Home » Stocks » VIVO

Meridian Bioscience, Inc. (VIVO)

Stock Price: $22.84 USD 1.25 (5.79%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 978.89M
Revenue (ttm) 253.67M
Net Income (ttm) 46.19M
Shares Out 42.86M
EPS (ttm) 1.07
PE Ratio 21.35
Forward PE 17.15
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $22.84
Previous Close $21.59
Change ($) 1.25
Change (%) 5.79%
Day's Open 22.40
Day's Range 22.12 - 23.00
Day's Volume 423,421
52-Week Range 5.57 - 26.41

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 5 days ago

Meridian Bioscience (VIVO) closed at $22.13 in the latest trading session, marking a +1.33% move from the prior day.

GlobeNewsWire - 6 days ago

CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fis...

Seeking Alpha - 1 week ago

Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus. Balance sheet safety, profit margins, revenue growth, and curr...

Zacks Investment Research - 1 week ago

Low-beta stocks may be able to help sail through the choppy market conditions.

Other stocks mentioned: LAKE, OMI, VSTO
Zacks Investment Research - 1 week ago

Bull of the Day: Meridian Bioscience (VIVO)

Benzinga - 1 week ago

Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicine...

Other stocks mentioned: TDOC, ARCT
Zacks Investment Research - 1 week ago

We have narrowed down our search to five small cap stocks that have strong growth potential for 2021. These are: SCHL, SCHN, RYI, PTSI, VIVO.

Other stocks mentioned: PTSI, RYI, SCHL, SCHN
Zacks Investment Research - 1 week ago

Investors always look for companies with a high level of profitability regardless of the ongoing market condition.

Other stocks mentioned: ABCB, BCEI, LAKE
Zacks Investment Research - 1 week ago

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: BJ, BLCM, LMNL, QFIN, VCNX
GlobeNewsWire - 1 week ago

CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participat...

Zacks Investment Research - 2 weeks ago

Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research - 2 weeks ago

Is (VIVO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 3 weeks ago

Two Stocks With an Upward Moving Earnings Outlook.

Other stocks mentioned: STLD
The Motley Fool - 3 weeks ago

These stocks offer a mix of speculation and steady growth.

Other stocks mentioned: MKC, NWVCF
Zacks Investment Research - 3 weeks ago

Here are six best-performing stocks with substantial net profit margins that can contribute toward making an enriching portfolio.

Other stocks mentioned: AVNW, CSV, LAKE, PIPR, WYY
GuruFocus - 3 weeks ago

In my opinion, investors may want to consider the three stocks that are listed in this article, since they could meet the following value criteria:

Other stocks mentioned: JPM, UNH
GlobeNewsWire - 1 month ago

CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has b...

Zacks Investment Research - 1 month ago

Let's take a look at these six top-ranked stocks with impressive net profit margins for a winning portfolio.

Other stocks mentioned: AVNW, CSV, HRI, PIPR, SYX
Zacks Investment Research - 1 month ago

Is (VIVO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 1 month ago

CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has s...

Zacks Investment Research - 1 month ago

Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

GlobeNewsWire - 1 month ago

CINCINNATI, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced toda...

GlobeNewsWire - 1 month ago

CINCINNATI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Ke...

Zacks Investment Research - 2 months ago

To combat the choppy market conditions, it is of utmost importance to create a portfolio of low-beta stocks.

Other stocks mentioned: AZRE, EGOV, SMP, VSTO
Zacks Investment Research - 2 months ago

Is (VIVO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 2 months ago

CINCINNATI, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President a...

Seeking Alpha - 2 months ago

Meridian Bioscience's (VIVO) CEO Jack Kenny on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 35.71% and 7.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 2 months ago

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report fourth quarter an...

InvestorPlace - 3 months ago

Despite the huge market rally since March, there are still some great value buys among small-cap stocks, if you know where to look. The post 7 Overlooked Small-Cap Stocks To Buy For Growth app...

Other stocks mentioned: CLFD, CWH, EGAN, GRBK, GSHD, SGC
GlobeNewsWire - 3 months ago

CINCINNATI, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that ...

GlobeNewsWire - 4 months ago

CINCINNATI, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science critical raw materials, is please...

GlobeNewsWire - 4 months ago

CINCINNATI, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President...

Seeking Alpha - 5 months ago

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 129.17% and 28.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 5 months ago

CINCINNATI, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020.

Zacks Investment Research - 5 months ago

Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line.

Zacks Investment Research - 5 months ago

Meridian Bioscience (VIVO) closed at $24.49 in the latest trading session, marking a -1.84% move from the prior day.

Zacks Investment Research - 5 months ago

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

CINCINNATI, July 28, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately.

GlobeNewsWire - 6 months ago

CINCINNATI, July 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2...

GlobeNewsWire - 6 months ago

CINCINNATI, July 13, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today tha...

Zacks Investment Research - 6 months ago

Is (VIVO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 6 months ago

Keeping the coronavirus impact in mind, we have shortlisted five stocks that can return well on investment in the second half of 2020.

Other stocks mentioned: FTNT, NEE
Zacks Investment Research - 6 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: EXPI, ICLK, KNSA, LAKE
The Motley Fool - 6 months ago

Meridian Bioscience has thrived during the COVID-19 pandemic. Can this stock go much higher, or is it time to cash out?

InvestorPlace - 7 months ago

This selection of growth stocks includes some surprise choices and companies set to benefit from the lasting effects of the pandemic.

Other stocks mentioned: ACLS, FORM, LOGI, TNK, ZM, ZYXI
Zacks Investment Research - 7 months ago

Meridian Bioscience (VIVO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

GlobeNewsWire - 7 months ago

CINCINNATI, May 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that...

About VIVO

Meridian Bioscience, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoas... [Read more...]

Industry
Diagnostics & Research
CEO
John Kenny
Employees
750
Stock Exchange
NASDAQ
Ticker Symbol
VIVO
Full Company Profile

Financial Performance

In 2020, VIVO's revenue was $253.67 million, an increase of 26.19% compared to the previous year's $201.01 million. Earnings were $46.19 million, an increase of 89.43%.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for VIVO stock is "Buy." The 12-month stock price forecast is 26.67, which is an increase of 16.77% from the latest price.

Price Target
$26.67
(16.77% upside)
Analyst Consensus: Buy